Hypnotic Intake and Motor and Cognitive Performances at High Altitude

Centre d'Expertise sur l'Altitude EXALT22 enrolled

Overview

This study aims to determine the effect of acute hypnotic intake (Zolpidem) on sleep, cognitive and motor performances and on acute mountain sickness symptoms at high altitude. Healthy subjects will be evaluated on 4 occasions (twice at sea level and twice at high altitude), after hypnotic or placebo intake. Following an early wake-up (01:00), symptoms, cognitive and motor performances will be assessed to determine potential residual effects of Zolpidem within such conditions.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

TRIPLE

Enrollment

Conditions

Physiology

Interventions

ZolpidemDRUG

The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.

PlaceboDRUG

The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * No sojourn above 2500 m during the past 2 months * Coffee intake \< 3 cups per day * Non-smoker Exclusion Criteria: * Respiratory, cardiovascular, metabolic or neuromuscular diseases * Psychiatric disorders * Use of hypnotics within the past year * Dependence syndrome (alcool, drugs, etc) * Severe insomnia or somnolence

Locations (1)

Grenoble University Hospital

Grenoble, Auvergne-Rhône-Alpes, France

Outcomes

Primary Outcomes

Cognitive performance assessed using Simon cognitive test

Simon cognitive test

Time frame: 4 hours after drug/placebo intake

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.